semaglutide 25 mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Semaglutide is similar to a natural hormone in your body (incretin) Type 2 diabetes: New Ozempic

Real-world data from compounded tirzepatide patients shows similar outcomes (14.2% weight loss at 72 weeks in a 2025 retrospective cohort, though this was not a controlled trial and patient populations differ)

Caractersticas tcnicas de la evaluacin del crecimiento Deben efectuarse mediciones seriadas de peso, longitud-talla y PC, y asentarlas en las grficas de crecimiento segn edad corregida (EC) hasta los 2 aos (edad corregida [EC]: se entiende por edad corregida, la que tendra el nio si hubiera nacido el da que cumpliera la 40 semana de gestacin)

Its essential to receive the injection only under a doctor's supervision

& Jacquot, J